BioLife Solutions, Inc. (NASDAQ:BLFS – Get Free Report) EVP Aby J. Mathew sold 10,000 shares of BioLife Solutions stock in a transaction dated Wednesday, September 18th. The stock was sold at an average price of $23.90, for a total value of $239,000.00. Following the transaction, the executive vice president now owns 317,716 shares of the company’s stock, valued at approximately $7,593,412.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
BioLife Solutions Trading Up 0.2 %
Shares of BLFS stock opened at $25.77 on Friday. The company has a current ratio of 2.86, a quick ratio of 1.81 and a debt-to-equity ratio of 0.04. The stock has a market cap of $1.19 billion, a P/E ratio of -18.15 and a beta of 1.87. The stock has a 50 day simple moving average of $24.17 and a 200 day simple moving average of $20.91. BioLife Solutions, Inc. has a 1 year low of $8.92 and a 1 year high of $26.73.
BioLife Solutions (NASDAQ:BLFS – Get Free Report) last issued its quarterly earnings results on Thursday, August 8th. The medical equipment provider reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.08. The business had revenue of $28.33 million during the quarter, compared to analysts’ expectations of $23.80 million. BioLife Solutions had a negative return on equity of 10.75% and a negative net margin of 59.88%. On average, research analysts predict that BioLife Solutions, Inc. will post -0.36 earnings per share for the current fiscal year.
Institutional Investors Weigh In On BioLife Solutions
Wall Street Analyst Weigh In
BLFS has been the subject of a number of research analyst reports. Northland Securities boosted their price objective on BioLife Solutions from $26.00 to $28.00 and gave the stock an “outperform” rating in a report on Friday, August 9th. Craig Hallum boosted their price objective on BioLife Solutions from $23.00 to $30.00 and gave the stock a “buy” rating in a report on Monday, August 12th. Finally, TD Cowen boosted their price objective on BioLife Solutions from $20.00 to $26.00 and gave the stock a “buy” rating in a report on Wednesday, July 17th. One equities research analyst has rated the stock with a sell rating and five have given a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $26.20.
View Our Latest Stock Report on BLFS
BioLife Solutions Company Profile
BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.
See Also
- Five stocks we like better than BioLife Solutions
- How to Use the MarketBeat Dividend Calculator
- Take Advantage of Village Farms Stock as Cannabis Market Evolves
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- MarketBeat Week in Review – 9/16 – 9/20
- The Role Economic Reports Play in a Successful Investment Strategy
- Don’t Miss These 3 Retail Stocks for Fall Gains
Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.